Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma × elotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 11 Recurrence 1 Neoplasms, Plasma Cell 1 Lymphoma 1

Interventions

Cyclophosphamide 54 Vincristine 52 Doxorubicin 50 Rituximab 43 Prednisone 40 Etoposide 33 Radiotherapy 32 Cytarabine 24 Filgrastim 20 Methotrexate 18 Bleomycin 18 Dexamethasone 16 Carmustine 13 Vinblastine 12 VAP-cyclo protocol 11 Prednisolone 11 Peripheral Blood Stem Cell Transplantation 11 Melphalan 11 Mitoxantrone 9 Mercaptopurine 9 Dacarbazine 9 Leucovorin 8 Procarbazine 7 Lenalidomide 7 Ifosfamide 7 Granulocyte Colony-Stimulating Factor 7 Gemcitabine 7 ibrutinib 6 Epoetin Alfa 6 Daunorubicin 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡